A Scientific Roadmap for Antibiotic Discovery

A sustained and robust pipeline of new antibacterial drugs and therapies is critical to preserve public health

A Scientific Roadmap for Antibiotics
Vials© The Pew Charitable Trusts

The roadmap outlines a concrete approach for the discovery of new antibiotics.

Overview

In recent decades, the discovery and development of new antibiotics have slowed dramatically as scientific barriers to drug discovery, regulatory challenges, and diminishing returns on investment have led major drug companies to scale back or abandon their antibiotic research. Consequently, antibiotic discovery—which peaked in the 1950s—has dropped precipitously. Of greater concern is the fact that nearly all antibiotics brought to market over the past 30 years have been variations on existing drugs.1 Every currently available antibiotic is a derivative of a class discovered between the early 1900s and 1984.2

At the same time, the emergence of antibiotic-resistant pathogens has accelerated, giving rise to life-threatening infections that will not respond to available antibiotic treatment. Inevitably, the more that antibiotics are used, the more that bacteria develop resistance—rendering the drugs less effective and leading public health authorities worldwide to flag antibiotic resistance as an urgent and growing public health threat.

Antibiotics Graphics

Reducing the inappropriate and unnecessary use of antibiotics will help slow this process, but it cannot halt it. Existing antibiotics will continue to lose their effectiveness over time, and patients will continue to need new drugs and therapies. Regulatory policies and economic incentives that encourage antibiotic development are vital; however, it is also critical to address fundamental gaps in basic scientific research that hinder new drug discovery.

The Pew Charitable Trusts convened a multidisciplinary group of leading industry and academic experts to identify the key scientific roadblocks to antibiotic discovery and consulted with numerous other public and private sector stakeholders to develop a Scientific Roadmap for Antibiotic Discovery. The roadmap outlines a concrete approach—both a scientific plan and organizational structure to support this research—that would lay a foundation for the sustained and diversified discovery and development of new antibiotics and therapies over the coming decades.

The report’s key findings show a need for:

  • A targeted approach to tackle the basic scientific barriers impeding antibiotic discovery and development.
  • A better understanding of how to overcome the cellular defenses of drug-resistant Gram-negative bacteria, which cause some of the most difficult-to-treat infections.
  • Generation of new chemical matter designed for antibiotic discovery.
  • Tools and methodologies to evaluate promising alternatives to traditional antibiotic use.
  • A framework for sharing information, expertise, and materials across the research community to foster innovative science and spur the discovery of novel antibacterial therapies.
Antibiotics Graphics

Success will require dedicated teams of multidisciplinary scientists to tackle key questions and share knowledge and skills across sectors.

  • A core scientific leadership group would set priorities and direct and manage milestone-driven research.
  • New methodologies and guidelines for antibiotic discovery generated by this initiative would provide scientists in industry and academia with a foundation to support the discovery of new drugs over a sustained period of time.
Antibiotics Graphics

If successfully implemented, this initiative has the potential to revitalize innovation in antibiotic research and accelerate the discovery of new types of antibacterial drugs and therapies.

ENDNOTES

  1. Lynn L. Silver, “Challenges of Antibacterial Discovery,” Clinical Microbiology Reviews 24, no. 1 (2011): 71–109, doi: 10.1128/CMR.00030-10.
  2. Cynthia C. Knapp and John A. Washington, “Antistaphylococcal Activity of a Cyclic Peptide, LY146032, and Vancomycin,” Antimicrobial Agents and Chemotherapy 30, no. 6 (1986): 938-939, doi: 10.1128/AAC.30.6.938; N. Allen et al., “LY146032 Inhibits the Biosynthesis of Cell Wall Peptidoglycan in Gram-positive Bacteria,” In Program and Abstracts of the 24th Interscience Conference on Antimicrobial Agents and Chemotherapy, p. 281. 1984; F. T. Counter et al., “LY146032 [N-(n-Decanoyl) A21978C nucleus] a New Acidic Lipopeptide Antibiotic: Synthesis and biological evaluation,” In Program and Abstracts of the 24th Interscience. Conference on Antimicrobial Agents and Chemotherapy, no. 1078, p. 281. 1984.

Download the full report.

Spotlight on Mental Health

scientist

This video is hosted by YouTube. In order to view it, you must consent to the use of “Marketing Cookies” by updating your preferences in the Cookie Settings link below. View on YouTube

This video is hosted by YouTube. In order to view it, you must consent to the use of “Marketing Cookies” by updating your preferences in the Cookie Settings link below. View on YouTube

Why Can't We Find New Antibiotics?
Drugs
Drugs
Press Releases & Statements

Pew Releases Scientific Roadmap to Spur Antibiotic Discovery and Innovation

Report proposes approach to end decades-long gap in new antibiotic approval

Quick View
Press Releases & Statements

The Pew Charitable Trusts today released a strategy to end the 30-year drought in the discovery of new types of antibiotics, key to fighting some of the most serious microbial threats. The Scientific Roadmap for Antibiotic Discovery identifies priority research goals and specific steps to break through the most significant scientific barriers impeding antibiotic discovery and to pave the way for urgently needed new drugs.

Drugs
Drugs
Article

Pew’s Scientific Roadmap for Antibiotic Discovery

Quick View
Article

The Pew Charitable Trusts released a strategy aimed at overcoming the 30-year drought in the discovery of new types of antibiotics.

Composite image of modern city network communication concept

Learn the Basics of Broadband from Our Limited Series

Sign up for our four-week email course on Broadband Basics

Quick View

How does broadband internet reach our homes, phones, and tablets? What kind of infrastructure connects us all together? What are the major barriers to broadband access for American communities?

Pills illustration
Pills illustration

What Is Antibiotic Resistance—and How Can We Fight It?

Sign up for our four-week email series The Race Against Resistance.

Quick View

Antibiotic-resistant bacteria, also known as “superbugs,” are a major threat to modern medicine. But how does resistance work, and what can we do to slow the spread? Read personal stories, expert accounts, and more for the answers to those questions in our four-week email series: Slowing Superbugs.

Explore Pew’s new and improved
Fiscal 50 interactive

Your state's stats are more accessible than ever with our new and improved Fiscal 50 interactive:

  • Maps, trends, and customizable charts
  • 50-state rankings
  • Analysis of what it all means
  • Shareable graphics and downloadable data
  • Proven fiscal policy strategies

Explore

Welcome to the new Fiscal 50

Key changes include:

  • State pages that help you keep track of trends in your home state and provide national and regional context.
  • Interactive indicator pages with highly customizable and shareable data visualizations.
  • A Budget Threads feature that offers Pew’s read on the latest state fiscal news.

Learn more about the new and improved Fiscal 50.